Hand-held technology from Baxter makes diabetic retinopathy screening simple and accessible for primary care settings

Early detection can prevent 95% of vision loss

SEOUL, South Korea, July 25, 2022 /PRNewswire/ — Diabetic retinopathy is the leading cause of blindness among working-age adults worldwide.1 With early detection and treatment, up to 95 percent of vision loss cases can be prevented.2 Compliance with annual diabetic retinal examinations in South Korea was found to be approximately 53%, with only 73% of these occurring in the past 12 months.3 Up to 80% of people with type two diabetes may eventually develop some stage of diabetic retinopathy.4

The Welch Allyn® RetinaVue™ 100 Imager PRO enables diabetic retinopathy screening in primary care settings. By quickly and conveniently screening patients as part of their routine primary care visit, RetinaVue has been shown to double patient compliance for potentially sight-saving annual diabetic retinal examinations (DRE) over 12 months.5


“Diabetes is an epidemic. Diabetic retinopathy is the leading cause of vision loss among adults ages 20 to 74.6 affecting 7.7 million people worldwide.7 It’s just tragic that a large percentage of patients with diabetes are not screened for diabetic retinopathy when it’s one of the most preventable causes of blindness among adults,” said Bruce Peaty, vice president of Baxter. Asia and the Pacific. “RetinaVue has the potential to change lives by helping to identify diabetic retinopathy in those individuals previously unscreened for the disease, raising the potential to save the sight of thousands, if not millions, of people with diabetes.”

Baxter makes this possible by lowering the cost barrier to high-quality fundus imaging. The RetinaVue 100 Imager PRO costs significantly less than full-size fundus cameras, yet the imager is designed so that any healthcare professional in a primary care practice can capture high-quality fundus images with minimal training.

With non-mydriatic capture through a 3.0 mm pupil, the RetinaVue 100 Imager PRO enables comfortable examinations without pharmacological dilation. The handheld portable device is an attractive solution for multi-location mobility. The solution uses proprietary contactless autofocus/image capture technology and integrated image quality assessment algorithms that can help reduce your need for reshoot appointments. You’ll get an instant grade on the quality of the image you capture.

The device will be available in South Korea begining July 25, 2022. Through RetinaVue, Baxter is committed to providing simple and affordable screening solutions to help preserve the vision of patients living with diabetes in primary care. For more information, please visit www.baxter.com or https://www.hillrom.kr/ko/solutions/combating-chronic-disease-apac/Diabetic-Retinopathy/

1. Diabetic retinopathy | Fred Hollows Foundation

2. Facts about diabetic eye diseases; the National Eye Institute (NEI); https://nei.nih.gov/health/diabetic/retinopathy

3. https://drbarometer.com/docs/default-source/dr-barometer-study-finding-documents/countries/south-korea/dr-barometer-south-korea-report.pdf?sfvrsn=e1f0cfdf_2 PAGE 134.

4. Lee DJ, Kumar N, Feuer WJ, et al. BMJ Open Diabetes Res Care. 2014; 2 (1): e000031.

5. Telemedicine and retinal imaging to improve the assessment of diabetic retinopathy; Archives of Internal Medicine; Volume 172, Issue 21, 2012

6. Updated: Centers for Disease Control and Prevention. Vision Health Initiative (VHI). https://www.cdc.gov/visionhealth/basics/ced/ Published September 29, 2015. Updated September 29, 2015. Accessed January 30, 2020.

7. National Eye Institute. Diabetic retinopathy facts and statistics. https://www.nei.nih.gov/learn-about-eye-health/resources-for-health-educators/eye-health-data-and-statistics/diabetic-retinopathy-data-and-statistics Posted on 17 July 2019. Updated July 17, 2019. Accessed February 24, 2020.

About Baxter

Every day, millions of patients, caregivers and healthcare providers rely on Baxter’s leading portfolio of diagnostic, critical care, renal care, nutrition, hospital and surgical products used in patient homes, hospitals, doctor’s offices and other places to care For 90 years, we’ve worked at the critical intersection where the innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter employees around the world are now building on the company’s rich legacy of medical breakthroughs to advance the next generation of transformative healthcare innovation. To learn more, visit www.baxter.com and follow us TwitterLinkedIn and Facebook.

CONTACT INFORMATION

Investor Relations

Media

Contact:

Claire Trachtman,

Vice President,
Investor Relations

Contact:

Bella Ling, Senior Director of

communications,

APAC and Greater China

telephone:

312-819-9387

telephone:

+86 136 4196 2389

Email:

[email protected]

Email:

[email protected]

Leave a Comment